<!DOCTYPE html>
<html lang="en" dir="auto">

<head>
<head>
    <title>endocrinology</title>
    <meta charset="utf-8">
    <meta name="description"
        content="Website meta description for google search results go here" />
    <meta name="dc.relation" content="https://trxiv.yorks0n.com" />
    <meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
    <meta name="theme-color" content="#1A94D2" />

    

    
    
    
    <link rel="stylesheet" href="/css/main.min.css" media="screen">

</head>


<meta charset="utf-8">
<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
<meta name="robots" content="index, follow">
<title>endocrinology | TRxiv2</title>
<meta name="keywords" content="">
<meta name="description" content="Combination low dose sulphonylurea and DPP4 inhibitor have potent glucose effect through augmentation of beta cell function without increase in hypoglycaemia: a randomised crossover study.
Authors: Cordiner, R. L.; Bedair, K.; Mari, A.; Pearson, E. R.
Score: 2.6, Published: 2023-08-24 DOI: 10.1101/2023.08.22.23294403
Aims/Hypothesis. it is important to address our use of cheaper generic therapies for type 2 diabetes (T2DM as the global prevalence of type 2 diabetes (T2DM) will surpass 600 million by 2035.">
<meta name="author" content="">
<link rel="canonical" href="https://trxiv.yorks0n.com/posts/endocrinology/">
<link crossorigin="anonymous" href="/assets/css/stylesheet.904bd1e751cdd2a584fa6bed3fa1166dfd8ec9949ebfd0c4d69c5add5e17c23d.css" integrity="sha256-kEvR51HN0qWE&#43;mvtP6EWbf2OyZSev9DE1pxa3V4Xwj0=" rel="preload stylesheet" as="style">
<script defer crossorigin="anonymous" src="/assets/js/highlight.f413e19d0714851f6474e7ee9632408e58ac146fbdbe62747134bea2fa3415e0.js" integrity="sha256-9BPhnQcUhR9kdOfuljJAjlisFG&#43;9vmJ0cTS&#43;ovo0FeA="
    onload="hljs.initHighlightingOnLoad();"></script>
<link rel="icon" href="https://trxiv.yorks0n.com/favicon.ico">
<link rel="icon" type="image/png" sizes="16x16" href="https://trxiv.yorks0n.com/favicon-16x16.png">
<link rel="icon" type="image/png" sizes="32x32" href="https://trxiv.yorks0n.com/favicon-32x32.png">
<link rel="apple-touch-icon" href="https://trxiv.yorks0n.com/apple-touch-icon.png">
<link rel="mask-icon" href="https://trxiv.yorks0n.com/safari-pinned-tab.svg">
<meta name="theme-color" content="#2e2e33">
<meta name="msapplication-TileColor" content="#2e2e33">
<noscript>
    <style>
        #theme-toggle,
        .top-link {
            display: none;
        }

    </style>
    <style>
        @media (prefers-color-scheme: dark) {
            :root {
                --theme: rgb(29, 30, 32);
                --entry: rgb(46, 46, 51);
                --primary: rgb(218, 218, 219);
                --secondary: rgb(155, 156, 157);
                --tertiary: rgb(65, 66, 68);
                --content: rgb(196, 196, 197);
                --hljs-bg: rgb(46, 46, 51);
                --code-bg: rgb(55, 56, 62);
                --border: rgb(51, 51, 51);
            }

            .list {
                background: var(--theme);
            }

            .list:not(.dark)::-webkit-scrollbar-track {
                background: 0 0;
            }

            .list:not(.dark)::-webkit-scrollbar-thumb {
                border-color: var(--theme);
            }
        }

    </style>
</noscript><meta property="og:title" content="endocrinology" />
<meta property="og:description" content="Combination low dose sulphonylurea and DPP4 inhibitor have potent glucose effect through augmentation of beta cell function without increase in hypoglycaemia: a randomised crossover study.
Authors: Cordiner, R. L.; Bedair, K.; Mari, A.; Pearson, E. R.
Score: 2.6, Published: 2023-08-24 DOI: 10.1101/2023.08.22.23294403
Aims/Hypothesis. it is important to address our use of cheaper generic therapies for type 2 diabetes (T2DM as the global prevalence of type 2 diabetes (T2DM) will surpass 600 million by 2035." />
<meta property="og:type" content="article" />
<meta property="og:url" content="https://trxiv.yorks0n.com/posts/endocrinology/" /><meta property="article:section" content="posts" />
<meta property="article:published_time" content="2023-08-27T10:37:02+00:00" />
<meta property="article:modified_time" content="2023-08-27T10:37:02+00:00" />

<meta name="twitter:card" content="summary"/>
<meta name="twitter:title" content="endocrinology"/>
<meta name="twitter:description" content="Combination low dose sulphonylurea and DPP4 inhibitor have potent glucose effect through augmentation of beta cell function without increase in hypoglycaemia: a randomised crossover study.
Authors: Cordiner, R. L.; Bedair, K.; Mari, A.; Pearson, E. R.
Score: 2.6, Published: 2023-08-24 DOI: 10.1101/2023.08.22.23294403
Aims/Hypothesis. it is important to address our use of cheaper generic therapies for type 2 diabetes (T2DM as the global prevalence of type 2 diabetes (T2DM) will surpass 600 million by 2035."/>


<script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "BreadcrumbList",
  "itemListElement": [, 
    {
      "@type": "ListItem",
      "position":  2 ,
      "name": "Posts",
      "item": "https://trxiv.yorks0n.com/posts/"
    }, 
    {
      "@type": "ListItem",
      "position":  3 ,
      "name": "endocrinology",
      "item": "https://trxiv.yorks0n.com/posts/endocrinology/"
    }
  ]
}
</script>
<script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "BlogPosting",
  "headline": "endocrinology",
  "name": "endocrinology",
  "description": "Combination low dose sulphonylurea and DPP4 inhibitor have potent glucose effect through augmentation of beta cell function without increase in hypoglycaemia: a randomised crossover study.\nAuthors: Cordiner, R. L.; Bedair, K.; Mari, A.; Pearson, E. R.\nScore: 2.6, Published: 2023-08-24 DOI: 10.1101/2023.08.22.23294403\nAims/Hypothesis. it is important to address our use of cheaper generic therapies for type 2 diabetes (T2DM as the global prevalence of type 2 diabetes (T2DM) will surpass 600 million by 2035.",
  "keywords": [
    
  ],
  "articleBody": " Combination low dose sulphonylurea and DPP4 inhibitor have potent glucose effect through augmentation of beta cell function without increase in hypoglycaemia: a randomised crossover study.\nAuthors: Cordiner, R. L.; Bedair, K.; Mari, A.; Pearson, E. R.\nScore: 2.6, Published: 2023-08-24 DOI: 10.1101/2023.08.22.23294403\nAims/Hypothesis. it is important to address our use of cheaper generic therapies for type 2 diabetes (T2DM as the global prevalence of type 2 diabetes (T2DM) will surpass 600 million by 2035. Negative aspects of SU may be avoided by their use at low dose. We have previously shown that 20mg standard release gliclazide reduces plasma glucose through augmentation of the classical incretin effect, increased beta cell glucose sensitivity and late-phase incretin potentiation. We hypothesised that there would be potential synergy between low dose SU when given in combination with a DPP4i, without increased hypoglycaemia risk, and aimed to assess this in a randomised clinical trial. Methods 30 participants with T2DM (HbA1c \u003c64 mmol/mol) treated with diet or metformin monotherapy were recruited to a single-centre, open-label, randomised crossover study. Participants completed four, 14-day study periods in a random order: control, gliclazide 20mg once daily (SU), sitagliptin 100mg (DPP4i), or combination (SUDPP4i). A 2-hour mixed meal tolerance test was conducted at the end of each period. Beta-cell function was assessed by modelling. The primary outcome was the effect of treatment on beta cell glucose sensitivity. Secondary end points included frequency of blood glucose \u003c3mmol/l on continuous glucose monitoring, sub analysis by genotype (KNCJ11 E23K), and analysis by gender and body mass index. Results Linear mixed model estimates showed a potent additive, glucose lowering effect of low dose SU combination with DPP4. Mean glucose AUC (mean 95% CI) (mmol/l) was: Control 11.5 (10.7-12.3), DPP4i 10.2 (9.4-11.1), SU 9.7 (8.9-10.5), SUDPP4i 8.7 (7.9-9.5) (p \u003c0.001). Beta cell glucose sensitivity (pmol min-1 m-2mM-1) mirrored this additive effect: Control 71.5 (51.1-91.9), DPP4i 75.9 (55.7-96.0), SU 86.3 (66.1-106.4), SUDPP4i 94.1 (73.9-14.3) (p = 0.04). Glucose time in range \u003c3mmol/l on CGM (%) was unaffected: Control 1 (2-4), DPP4i 2 (3-6), SU 1 (0-4), SUDPP4i 3 (2-7) (p = 0.65). The increase in glucose sensitivity with sulphonylurea treatment was seen in men not women. Conclusions Combination low dose gliclazide with a DPP4i has potent glucose lowering effect through augmentation of beta cell function. Glucose reduction was achieved at gliclazide concentrations far below those achieved with standard therapeutic doses. A double-blind randomised controlled trial is merited to formalise efficacy and safety of this combination, which may avoid negative aspects of SU and provide pharmacoeconomic benefit in diabetes care.\n",
  "wordCount" : "422",
  "inLanguage": "en",
  "datePublished": "2023-08-27T10:37:02Z",
  "dateModified": "2023-08-27T10:37:02Z",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://trxiv.yorks0n.com/posts/endocrinology/"
  },
  "publisher": {
    "@type": "Organization",
    "name": "TRxiv2",
    "logo": {
      "@type": "ImageObject",
      "url": "https://trxiv.yorks0n.com/favicon.ico"
    }
  }
}
</script>
</head>

<body class="" id="top">
<script>
    if (localStorage.getItem("pref-theme") === "dark") {
        document.body.classList.add('dark');
    } else if (localStorage.getItem("pref-theme") === "light") {
        document.body.classList.remove('dark')
    } else if (window.matchMedia('(prefers-color-scheme: dark)').matches) {
        document.body.classList.add('dark');
    }

</script>

<header class="header">
    <nav class="nav">
        <div class="logo">
            <a href="https://trxiv.yorks0n.com" accesskey="h" title="TRxiv2 (Alt + H)">TRxiv2</a>
            <div class="logo-switches">
                <button id="theme-toggle" accesskey="t" title="(Alt + T)">
                    <svg id="moon" xmlns="http://www.w3.org/2000/svg" width="24" height="18" viewBox="0 0 24 24"
                        fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round"
                        stroke-linejoin="round">
                        <path d="M21 12.79A9 9 0 1 1 11.21 3 7 7 0 0 0 21 12.79z"></path>
                    </svg>
                    <svg id="sun" xmlns="http://www.w3.org/2000/svg" width="24" height="18" viewBox="0 0 24 24"
                        fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round"
                        stroke-linejoin="round">
                        <circle cx="12" cy="12" r="5"></circle>
                        <line x1="12" y1="1" x2="12" y2="3"></line>
                        <line x1="12" y1="21" x2="12" y2="23"></line>
                        <line x1="4.22" y1="4.22" x2="5.64" y2="5.64"></line>
                        <line x1="18.36" y1="18.36" x2="19.78" y2="19.78"></line>
                        <line x1="1" y1="12" x2="3" y2="12"></line>
                        <line x1="21" y1="12" x2="23" y2="12"></line>
                        <line x1="4.22" y1="19.78" x2="5.64" y2="18.36"></line>
                        <line x1="18.36" y1="5.64" x2="19.78" y2="4.22"></line>
                    </svg>
                </button>
            </div>
        </div>
        <ul id="menu">
        </ul>
    </nav>
</header>
<main class="main">
<article class="post-single">
  <header class="post-header">
    
    <h1 class="post-title">
      endocrinology
    </h1>
    <div class="post-meta"><span>updated on August 27, 2023</span>

</div>
  </header> 
  <div class="post-content"><div class="accordion accordion-flush" id="accordionFlushExample"><div class="accordion-item">
    <h3 class="accordion-header" id="flush-heading10.1101/2023.08.22.23294403">
      <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#flush-collapse10.1101/2023.08.22.23294403" aria-expanded="false" aria-controls="flush-collapse10.1101/2023.08.22.23294403">
        <p class="paperTitle">Combination low dose sulphonylurea and DPP4 inhibitor have potent glucose effect through augmentation of beta cell function without increase in hypoglycaemia: a randomised crossover study.</p>
      </button>
    </h3>
    <div id="flush-collapse10.1101/2023.08.22.23294403" class="accordion-collapse collapse" aria-labelledby="flush-heading10.1101/2023.08.22.23294403" data-bs-parent="#accordionFlushExample">
      <div class="accordion-body">
        <p class="author">Authors: Cordiner, R. L.; Bedair, K.; Mari, A.; Pearson, E. R.</p>
        <p class="info">Score: 2.6, Published: 2023-08-24 </p>
        <p class="info">DOI: <a href='https://doi.org/10.1101/2023.08.22.23294403' target='https://doi.org/10.1101/2023.08.22.23294403'> 10.1101/2023.08.22.23294403</a></p>
        <p class="abstract">Aims/Hypothesis. it is important to address our use of cheaper generic therapies for type 2 diabetes (T2DM as the global prevalence of type 2 diabetes (T2DM) will surpass 600 million by 2035. Negative aspects of SU may be avoided by their use at low dose. We have previously shown that 20mg standard release gliclazide reduces plasma glucose through augmentation of the classical incretin effect, increased beta cell glucose sensitivity and late-phase incretin potentiation. We hypothesised that there would be potential synergy between low dose SU when given in combination with a DPP4i, without increased hypoglycaemia risk, and aimed to assess this in a randomised clinical trial. Methods 30 participants with T2DM (HbA1c &lt;64 mmol/mol) treated with diet or metformin monotherapy were recruited to a single-centre, open-label, randomised crossover study. Participants completed four, 14-day study periods in a random order: control, gliclazide 20mg once daily (SU), sitagliptin 100mg (DPP4i), or combination (SUDPP4i). A 2-hour mixed meal tolerance test was conducted at the end of each period. Beta-cell function was assessed by modelling. The primary outcome was the effect of treatment on beta cell glucose sensitivity. Secondary end points included frequency of blood glucose &lt;3mmol/l on continuous glucose monitoring, sub analysis by genotype (KNCJ11 E23K), and analysis by gender and body mass index. Results Linear mixed model estimates showed a potent additive, glucose lowering effect of low dose SU combination with DPP4. Mean glucose AUC (mean 95% CI) (mmol/l) was: Control 11.5 (10.7-12.3), DPP4i 10.2 (9.4-11.1), SU 9.7 (8.9-10.5), SUDPP4i 8.7 (7.9-9.5) (p &lt;0.001). Beta cell glucose sensitivity (pmol min-1 m-2mM-1) mirrored this additive effect: Control 71.5 (51.1-91.9), DPP4i 75.9 (55.7-96.0), SU 86.3 (66.1-106.4), SUDPP4i 94.1 (73.9-14.3) (p = 0.04). Glucose time in range &lt;3mmol/l on CGM (%) was unaffected: Control 1 (2-4), DPP4i 2 (3-6), SU 1 (0-4), SUDPP4i 3 (2-7) (p = 0.65). The increase in glucose sensitivity with sulphonylurea treatment was seen in men not women. Conclusions Combination low dose gliclazide with a DPP4i has potent glucose lowering effect through augmentation of beta cell function. Glucose reduction was achieved at gliclazide concentrations far below those achieved with standard therapeutic doses. A double-blind randomised controlled trial is merited to formalise efficacy and safety of this combination, which may avoid negative aspects of SU and provide pharmacoeconomic benefit in diabetes care.</p>
      </div>
    </div>
  </div>
</div>









<script src="/js/bundle.min.js" defer></script>



  </div>

  <footer class="post-footer">
    <ul class="post-tags">
    </ul>
  </footer>
</article>
    </main>
    
<footer class="footer">
    <span>&copy; 2023 <a href="https://trxiv.yorks0n.com">TRxiv2</a></span>
    <span>
        · Made by Yorkson
    </span>
</footer>
<a href="#top" aria-label="go to top" title="Go to Top (Alt + G)" class="top-link" id="top-link" accesskey="g">
    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 12 6" fill="currentColor">
        <path d="M12 6H0l6-6z" />
    </svg>
</a>

<script>
    let menu = document.getElementById('menu')
    if (menu) {
        menu.scrollLeft = localStorage.getItem("menu-scroll-position");
        menu.onscroll = function () {
            localStorage.setItem("menu-scroll-position", menu.scrollLeft);
        }
    }

    document.querySelectorAll('a[href^="#"]').forEach(anchor => {
        anchor.addEventListener("click", function (e) {
            e.preventDefault();
            var id = this.getAttribute("href").substr(1);
            if (!window.matchMedia('(prefers-reduced-motion: reduce)').matches) {
                document.querySelector(`[id='${decodeURIComponent(id)}']`).scrollIntoView({
                    behavior: "smooth"
                });
            } else {
                document.querySelector(`[id='${decodeURIComponent(id)}']`).scrollIntoView();
            }
            if (id === "top") {
                history.replaceState(null, null, " ");
            } else {
                history.pushState(null, null, `#${id}`);
            }
        });
    });

</script>
<script>
    var mybutton = document.getElementById("top-link");
    window.onscroll = function () {
        if (document.body.scrollTop > 800 || document.documentElement.scrollTop > 800) {
            mybutton.style.visibility = "visible";
            mybutton.style.opacity = "1";
        } else {
            mybutton.style.visibility = "hidden";
            mybutton.style.opacity = "0";
        }
    };

</script>
<script>
    document.getElementById("theme-toggle").addEventListener("click", () => {
        if (document.body.className.includes("dark")) {
            document.body.classList.remove('dark');
            localStorage.setItem("pref-theme", 'light');
        } else {
            document.body.classList.add('dark');
            localStorage.setItem("pref-theme", 'dark');
        }
    })

</script>
</body>

</html>
